Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Oral phosphate purgative is the preferred bowel regimen on the basis of better tolerability, cost effectiveness, and efficacy. There are also numerous reports of patients with even previously normal renal function developing acute and chronic kidney disease after use of oral phosphate purgative. Several uncontrolled case reports and case series suggest a potential link between oral phosphate and acute kidney injury and/or chronic kidney disease1. Its use is contraindicated in patients with preexisting renal disease because of the risk for developing acute renal failure, so called acute phosphate nephropathy, or electrolyte disturbance. Since most of the outpatients who are going to undergo a colonoscopy are exposed to this agent, it is important to detect or prevent vulnerable patients. We would seek a sensitive and rapid diagnosis method of acute kidney injury following sodium phosphate bowel preparation. Within a few hours, NGAL mRNA is highly upregulated after kidney injury, such as renal ischemia-reperfusion and cisplatin nephropathy, NGAL induction precedes the elevation of classical markers for kidney damage such as serum creatinine. The investigators will investigate the change of NGAL following sodium phosphate bowel preparation.
| Condition |
|---|
|
Acute Kidney Failure |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Change of Neutrophil Gelatinase-Associated Lipocalin(NGAL) Following Sodium Phosphate Bowel Preparation(Pilot Study) |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
18-65 year old volunteers who want to get colonoscopy
Exclusion Criteria:
- Who takes ACE-inhibitor, ARB
- Has a renal or heart disease
- Has a serum electrolyte disturbance
Contacts and Locations| Contact: Soon Hyo Kwon, MD | +8-02-709-9491 | ksoonhyo@hosp.sch.ac.kr |
| Korea, Republic of | |
| Soon Chun Hyang University Hospital | Recruiting |
| Seoul, Korea, Republic of, 140-743 | |
| Contact: Soon Hyo Kwon, MD +8-02-709-9491 ksoonhyo@hosp.sch.ac.kr | |
| Principal Investigator: Dong Cheol Han, MD | |
More Information
No publications provided
| Responsible Party: | Dong Cheol Han MD, Soon Chun Hyang University |
| ClinicalTrials.gov Identifier: | NCT00760591 History of Changes |
| Other Study ID Numbers: | 2008-41 |
| Study First Received: | September 25, 2008 |
| Last Updated: | September 25, 2008 |
| Health Authority: | Korea: Food and Drug Administration |
Keywords provided by Soon Chun Hyang University:
|
Acute kidney failure Colonoscopy Neutrophil gelatinase-associated lipocalin |
Additional relevant MeSH terms:
|
Acute Kidney Injury Renal Insufficiency Kidney Diseases Urologic Diseases Sodium phosphate |
Cathartics Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013